Voyager Therapeutics operates under the executive leadership of Alfred Sandrock, Jr., M.D., who serves as the Chief Executive Officer and a member of the Board of Directors. Bringing decades of distinguished biopharmaceutical experience—including serving as head of research and development at Biogen, where he oversaw the creation and regulatory approval of several breakthrough neurological therapies—he directs Voyager's strategic focus on advancing innovative gene and precision neuromedicines designed to treat severe central nervous system disorders.